tirzepatide compound fda lawsuit Eli Lilly sues companies selling alternative versions of its weight loss drug FDA reviews decision to put

Clinical Evidence for GLP-1 and DPP-4 Combination Use Medical literature on simultaneous GLP-1 agonist and DPP-4 inhibitor use remains limited, and combination therapy is not routinely recommended by major diabetes guidelines

Add more layers of clothing, drink a warm beverage, or move around to generate heat

Changing Medications Transitioning to alternative weight management medications can also be beneficial

When to contact a healthcare provider: Persistent vomiting, severe abdominal pain, signs of dehydration (dark urine, dizziness, dry mouth), or any symptoms that prevent normal daily activities

Ann.Nutr.Metab 2008;53(2):91-95